Collaborative Arrangements - CRISPR Therapeutics AG (Details) - USD ($) |
1 Months Ended | 3 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
Jul. 31, 2019 |
Dec. 31, 2019 |
Sep. 30, 2019 |
Dec. 31, 2019 |
Dec. 31, 2018 |
Dec. 31, 2017 |
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
| Investment in collaborative partner, pursuant to convertible loan agreement | $ 63,300,000 | $ 46,900,000 | $ 8,700,000 | |||
| CRISPR Therapeutics | ||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
| Collaborative funding | $ 30,000,000.0 | |||||
| Collaborative arrangement development and regulatory potential milestone payments maximum | $ 825,000,000.0 | 410,000,000.0 | ||||
| Collaborative arrangement, development and commercialization rights potential maximum milestone payments | $ 175,000,000.0 | |||||
| CTX001 Co-Co Agreement | ||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
| Collaborative arrangement research and development expenses | $ 30,100,000 | $ 19,700,000 | ||||